Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2015-10-21
2035-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus
NCT04744636
Characterization of Type 2 Diabetes Subgroups at Diagnosis: a Necessary Step Towards Precision Medicine in Diabetes.
NCT05333718
Epigenetics Based Diagnosis of Diabetes in Saliva and Blood Samples
NCT04011228
Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications
NCT07250607
Screening and Understanding of the Pre-diabetes: DECODIAB
NCT01739868
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Despite well-controlled established cardiovascular risk factors, the residual risk in subjects with diabetes mellitus is significantly higher than the risk in those without the condition and it is well established that current risk prediction models for cardiovascular disease using established risk factors do not fully explain the future cardiovascular risk.
Therefore, biomarker for better risk stratification are needed, in particular in subjects with diabetes mellitus. Prospective cohorts, meticulously clinically phenotyping subjects, regularly following them and collecting biomarker samples is one key approach for finding new biomarker panels, that are predictive of treatment response and future micro- and macrovascular complications.
The Diabetes registry for Biomarker Research Graz was initiated in November 2015. Subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity or dyslipidemia are recruited in the outpatient clinic for Diabetes, Lipid and Metabolic Disorders at the University Clinic Graz or in the Rehabilitation Center St. Radegund.
As of September 2021, 1250 subjects are recruited. Blood and urine samples samples are collected at baseline and at annual follow up visits as well as data on medical history, diagnoses and medication.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 1 Diabetes
Patients with diagnosed type 1 diabetes mellitus
No intervention
In this registry no intervention is carried out
Type 2 Diabetes
Patients with diagnosed type 2 diabetes mellitus
No intervention
In this registry no intervention is carried out
Adipositas
Obese patients with a BMI \> 30kg/m2
No intervention
In this registry no intervention is carried out
Lipid metabolism disorder
Patients with disorder of lipid metabolism
No intervention
In this registry no intervention is carried out
Type 3 Diabetes Mellitus
Patients with diagnosed type 3 diabetes mellitus
No intervention
In this registry no intervention is carried out
Maturity onset diabetes of the young (MODY)
Patients with diagnosed MODY
No intervention
In this registry no intervention is carried out
Late onset diabetes of the adult (LADA)
Patients with diagnosed LADA
No intervention
In this registry no intervention is carried out
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
In this registry no intervention is carried out
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent has to be given in written form
* At least one of the following diseases:
* Type 1 diabetes
* Type 2 diabetes
* Type 3 diabetes
* Maturity onset diabetes of young (MODY)
* Late onset diabetes of the adult (LADA)
* Adipositas (BMI \> 30kg/m2)
* Lipid metabolism disorder
Exclusion Criteria
* No willingness to participate in this registry
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Harald Sourij, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Graz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Graz
Graz, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HS-2015-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.